Holen Sie sich die Stockscreener-App
1.30
3.17%
0.04
Handel nachbörslich:
1.30
Schlusskurs vom Vortag:
$1.26
Offen:
$1.26
24-Stunden-Volumen:
887.93K
Relative Volume:
1.65
Marktkapitalisierung:
$54.91M
Einnahmen:
$88.55M
Nettoeinkommen (Verlust:
$-53.21M
KGV:
-1.0047
EPS:
-1.2939
Netto-Cashflow:
$-29.48M
1W Leistung:
-2.26%
1M Leistung:
-5.11%
6M Leistung:
-37.80%
1J Leistung:
-61.42%
1-Tages-Spanne:
$1.21
$1.30
1-Wochen-Bereich:
$1.21
$1.365
52-Wochen-Spanne:
$1.13
$3.88
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.30 | 53.22M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash - Stock Titan
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary - TradingView
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
Pulmonx Corporation (NASDAQ:LUNG) Q1 2026 Earnings Call Transcript - Insider Monkey
LUNG Maintained by D. Boral Capital -- Price Target Stays at $14 - GuruFocus
Pulmonx Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Pulmonx's (LUNG) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus
Is Pulmonx (LUNG) 85.3% Undervalued After Q1 2026 Beats? EPS -$0 - GuruFocus
Pulmonx (LUNG) Projects 2026 Revenue Between $90M and $92M - GuruFocus
Pulmonx Q1 Earnings Call Highlights - MarketBeat
Pulmonx (LUNG) Reports Strong Q1 Revenue Growth - GuruFocus
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips - Investing.com Canada
Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Pulmonx Corp (NASDAQ:LUNG) Q1 2026 Revenue Miss and Falling Sales Drag Down Sentiment - ChartMill
Pulmonx (NASDAQ:LUNG) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Pulmonx Reports First Quarter 2026 Financial Results - The Manila Times
Pulmonx (NASDAQ: LUNG) Q1 revenue falls 9% but 2026 outlook reaffirmed - Stock Titan
No China sales cut Pulmonx revenue 9%, but 2026 forecast holds - Stock Titan
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference - The Manila Times
Pulmonx webcast set for May 12 Bank of America health conference - Stock Titan
LUNG (Pulmonx Corporation) rises 5.63% on narrower Q4 2025 losses and steady 8% year over year revenue growth.Management Guidance - UBND thành phố Hải Phòng
[ARS] Pulmonx Corp SEC Filing - Stock Titan
Executive pay and board votes at Pulmonx (NASDAQ: LUNG) 2026 meeting - Stock Titan
Pulmonx (LUNG) Projected to Post Earnings on Wednesday - MarketBeat
Pulmonx Corporation (LUNG) Stock: Trendline Analysis (-1.13%) 2026-04-22Hot Momentum Watchlist - newser.com
How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk - Yahoo Finance
Pulmonx Corporation (NASDAQ:LUNG) Short Interest Update - MarketBeat
Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast - Stock Titan
LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside? - AD HOC NEWS
Pulmonx (NASDAQ:LUNG) Stock Price Up 2.3%Still a Buy? - MarketBeat
Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - Sahm
How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - Yahoo Finance
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com
Rate Hike: Is Pulmonx Corporation stock trending bullishWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan
If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan
How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther - AD HOC NEWS
Growth Value: Should I set a stop loss on Pulmonx CorporationBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Pulmonx Corporation 2025 Annual Report: Innovative COPD Solutions, Zephyr Valve Clinical Data, and Global Market Strategy - Minichart
LUNG Technical Analysis & ETF Price Forecast - Intellectia AI
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):